Epigenomics Core: newer DNA regulation services for researchers
Official title: Epigenomics Core
Funded at Oklahoma Medical Research Foundation · NIH-11349613 · Data updated 2026-11-12
A core facility upgrade at a medical research center will add advanced DNA accessibility, protein binding, and long-read sequencing services to support genomic regulation and immunity studies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma Medical Research Foundation NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | June 10, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $246,431 |
| NIH project number | 5P20GM156711-02 |
| Project ID | NIH-11349613 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with immune-related conditions whose biology is studied through genomic regulation approaches or who participate via data or sample contributions in future translational projects.
✕Less likely to help
Patients not directly involved in immune-regulation research or unrelated conditions may not experience direct benefits from this core.
What this research studies
If you’re a patient near Oklahoma City, this project helps scientists access state-of-the-art tools to study how genes are turned on or off in immune cells. The Epigenomics Core will expand capabilities like ATAC-seq, CUT&RUN/CUT&TAG, ChIP-seq, and long-read sequencing to support diverse user projects. By improving these services, researchers can translate findings about gene regulation into better understanding of immune-related diseases and their treatment. The core focuses on enabling researchers to generate high-quality data more efficiently and sustainably at OKMRF.
Why it matters
Potential benefit: It could accelerate discoveries that improve diagnosis, treatment, and prevention of immune-related conditions.
How similar studies have gone: Other institutions have successfully expanded cores to provide chromatin accessibility and binding protein analyses, showing strong potential for impactful research advances.
Where this research is happening
-
Oklahoma Medical Research Foundation
Oklahoma City, United States Active
Researchers
- Principal investigator: Wiley, Graham — Oklahoma Medical Research Foundation
- Study coordinator: Wiley, Graham
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.